RECORD // Company

Vir Biotechnology, Inc.

Built 2026-11-21T11:22:38Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (8)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Vir Biotechnology, Inc. · Ca business · same registered legal name as 'Vir Biotechnology, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Vir Biotechnology, Inc. · Ca business · same registered legal name as 'Vir Biotechnology, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Vir Biotechnology, Inc. · Ca business · same registered legal name as 'Vir Biotechnology, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Vir Biotechnology, Inc. · Ctgov · same registered legal name as 'Vir Biotechnology, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • VIR BIOTECHNOLOGY, INC. · East licences · same registered legal name as 'Vir Biotechnology, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • VIR BIOTECHNOLOGY INC · Epa echo · same registered legal name as 'Vir Biotechnology, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • VIR BIOTECHNOLOGY INC · Epa echo · same registered legal name as 'Vir Biotechnology, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • VIR BIOTECHNOLOGY, INC. · USAspending · same registered legal name as 'Vir Biotechnology, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

4 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-04 · accession 0001628280-26-070273

ItemValuePeriodFormFiledAccessionReport
Revenue$-188,0003 months ended 2026-09-3010-Q2026-11-040001628280-26-0702732026-11-21 11:22 UTCReport an error
Net income (loss)$-96,252,0003 months ended 2026-09-3010-Q2026-11-040001628280-26-0702732026-11-21 11:22 UTCReport an error
Cash and cash equivalents$218,866,000at 2026-09-3010-Q2026-11-040001628280-26-0702732026-11-21 11:22 UTCReport an error
Contract liabilities, current (from an earlier report)$0at 2025-12-3110-K2026-02-230001628280-26-0107492026-11-21 11:22 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001706431
Ticker
VIR
EIN
812730369
CUSIP
92764N102
Record ID
sx:sec:0001706431

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

41 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-21 11:22 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-16SEC EDGAR company profile2026-11-21 11:22 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-21 11:22 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-21 11:22 UTCReport an error
Business address1800 OWENS STREET, SUITE 900, SAN FRANCISCO, CA, 941582026-11-16SEC EDGAR company profile2026-11-21 11:22 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-21 11:22 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$68,556,0002025-12-3110-K, XBRL Revenues2026-11-21 11:22 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-437,987,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 11:22 UTCReport an error
Total assets (at 2025-12-31)$1,002,823,0002025-12-3110-K, XBRL Assets2026-11-21 11:22 UTCReport an error
Stockholders' equity (at 2025-12-31)$765,276,0002025-12-3110-K, XBRL StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest2026-11-21 11:22 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$232,185,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 11:22 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-391,781,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 11:22 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$4,832,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 11:22 UTCReport an error
Operating lease liabilities (at 2025-12-31)$97,852,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 11:22 UTCReport an error
Form D total offering amount (D filed 2020-05-08)$32,444,4412020-05-08D2026-11-21 11:22 UTCReport an error
Form D total amount sold (D filed 2020-05-08)$32,444,4412020-05-08D2026-11-21 11:22 UTCReport an error
Form D industry groupBiotechnology2020-05-08D2026-11-21 11:22 UTCReport an error
Form D revenue rangeDecline to Disclose2020-05-08D2026-11-21 11:22 UTCReport an error
Form D date of first sale2020-05-062020-05-08D2026-11-21 11:22 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-09)Vir Biotechnology, Inc. (the Company) is holding a virtual investor conference call at 5:30 a.m. PT / 8:30 a.m. ET on November 9, 2026, to discuss the topline results from the pivotal Phase 3 ECLIPSE 1 clinical trial evaluating monthly subcutaneous administration of the combination regimen of elebsiran, an investigational small interfering RNA (siRNA), and tobevibart, an investigational monoclonal antibody, in adults with chronic hepatitis delta (CHD) (such results, the ECLIPSE 1 TLR), as well as expanded data and an exploratory analysis from the Phase 2 SOLSTICE study evaluating the combination regimen and tobevibart monotherapy in adults with CHD (such data and analysis, the SOLSTICE…2026-11-09SEC EDGAR 8-K 0001628280-26-071908 (text as filed, excerpt)2026-11-21 11:22 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-09)ECLIPSE 1 TLR Certain data from the ongoing Phase 3 ECLIPSE 1 clinical trial, including the ECLIPSE 1 TLR, were presented in an oral session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, in Denver, Colorado on November 8, 2026. ECLIPSE 1 enrolled a total of 124 patients, randomized 2:1, to receive monthly subcutaneous elebsiran and tobevibart or delayed treatment, with the delayed treatment group initiating therapy at Week 12. The trial enrolled a broad and diverse CHD population across multiple countries and included patients with advanced disease. The trial’s primary endpoint was met, with a 44% response rate in patients receiving elebsiran and…2026-11-09SEC EDGAR 8-K 0001628280-26-071908 (text as filed, excerpt)2026-11-21 11:22 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-04)On November 4, 2026, Vir Biotechnology, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act…2026-11-04SEC EDGAR 8-K 0001628280-26-070148 (text as filed, excerpt)2026-11-21 11:22 UTCReport an error
Employer name (as filed)Vir Biotechnology, Inc.2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:22 UTCReport an error
Certified LCAs22026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:22 UTCReport an error
Certified LCAs later withdrawn02026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:22 UTCReport an error
Total worker positions on certified LCAs22026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:22 UTCReport an error
Top job titles (title, LCA count)Senior Research Associate (1); Sr. Manager, Biostatistics (1)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:22 UTCReport an error
Wage offered, annualized (n, min, median, max)median $147,230 (range $108,159-$186,300, 2 filings)2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:22 UTCReport an error
Worksite statesCA; FL2026-06-30DOL OFLC LCA Disclosure Data (dataset)2026-11-21 11:22 UTCReport an error
Plan (pension, plan no. 001)VIR BIOTECHNOLOGY 401(K) PLAN: 607 participants, assets $86,293,0282025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 11:22 UTCReport an error
Plan (welfare, plan no. 501)VIR BIOTECHNOLOGY, INC. WELFARE BENEFITS PLAN: 329 participants2025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-21 11:22 UTCReport an error
Largest institutional holder #1 (13F as filed): BlackRock, Inc.$210,711,7052026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:22 UTCReport an error
Largest institutional holder #2 (13F as filed): ARCH Venture Management, LLC$129,353,5212026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:22 UTCReport an error
Largest institutional holder #3 (13F as filed): VANGUARD PORTFOLIO MANAGEMENT LLC$117,136,2412026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:22 UTCReport an error
Largest institutional holder #4 (13F as filed): SB INVESTMENT ADVISERS (UK) LTD$111,561,0682026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:22 UTCReport an error
Largest institutional holder #5 (13F as filed): STATE STREET CORP$101,534,6992026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:22 UTCReport an error
Largest institutional holder #6 (13F as filed): GSK plc$87,134,2212026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:22 UTCReport an error
Largest institutional holder #7 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$65,101,6172026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:22 UTCReport an error
Largest institutional holder #8 (13F as filed): Point72 Asset Management, L.P.$57,744,9062026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:22 UTCReport an error
Largest institutional holder #9 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$34,124,7082026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:22 UTCReport an error
Largest institutional holder #10 (13F as filed): DIMENSIONAL FUND ADVISORS LP$31,789,6272026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 11:22 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.